DOP2017000156A - Derivados de glucagón con estabilidad mejorada - Google Patents
Derivados de glucagón con estabilidad mejoradaInfo
- Publication number
- DOP2017000156A DOP2017000156A DO2017000156A DO2017000156A DOP2017000156A DO P2017000156 A DOP2017000156 A DO P2017000156A DO 2017000156 A DO2017000156 A DO 2017000156A DO 2017000156 A DO2017000156 A DO 2017000156A DO P2017000156 A DOP2017000156 A DO P2017000156A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- glucagon
- present
- improved stability
- hypoglycemia
- prevention
- Prior art date
Links
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical class C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 title abstract 5
- 102000051325 Glucagon Human genes 0.000 abstract 2
- 108060003199 Glucagon Proteins 0.000 abstract 2
- 208000013016 Hypoglycemia Diseases 0.000 abstract 2
- 229960004666 glucagon Drugs 0.000 abstract 2
- 230000002218 hypoglycaemic effect Effects 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 108010063919 Glucagon Receptors Proteins 0.000 abstract 1
- 102100040890 Glucagon receptor Human genes 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000000883 anti-obesity agent Substances 0.000 abstract 1
- 239000003472 antidiabetic agent Substances 0.000 abstract 1
- 229940125710 antiobesity agent Drugs 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 229940126904 hypoglycaemic agent Drugs 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 230000000704 physical effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20140193800 | 2014-12-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DOP2017000156A true DOP2017000156A (es) | 2017-10-15 |
Family
ID=56284642
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2017000156A DOP2017000156A (es) | 2014-12-30 | 2017-06-29 | Derivados de glucagón con estabilidad mejorada |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US11135271B2 (show.php) |
| EP (2) | EP3241841A4 (show.php) |
| JP (2) | JP6797122B2 (show.php) |
| KR (1) | KR102291020B1 (show.php) |
| CN (1) | CN107636009B (show.php) |
| AR (1) | AR103322A1 (show.php) |
| AU (1) | AU2015372818A1 (show.php) |
| CL (1) | CL2017001718A1 (show.php) |
| CO (1) | CO2017006308A2 (show.php) |
| CR (1) | CR20170293A (show.php) |
| DO (1) | DOP2017000156A (show.php) |
| EA (1) | EA035527B1 (show.php) |
| EC (1) | ECSP17040923A (show.php) |
| ES (1) | ES2976562T3 (show.php) |
| GT (1) | GT201700150A (show.php) |
| HK (1) | HK1248713A1 (show.php) |
| IL (2) | IL253206B (show.php) |
| MA (1) | MA40709B1 (show.php) |
| MX (1) | MX2017008569A (show.php) |
| MY (1) | MY185334A (show.php) |
| PE (2) | PE20230304A1 (show.php) |
| PH (1) | PH12017501222B1 (show.php) |
| SG (1) | SG11201705376SA (show.php) |
| TN (1) | TN2017000271A1 (show.php) |
| TW (1) | TW201639878A (show.php) |
| UA (1) | UA126960C2 (show.php) |
| WO (1) | WO2016108586A1 (show.php) |
| ZA (1) | ZA201705015B (show.php) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20230304A1 (es) * | 2014-12-30 | 2023-02-13 | Hanmi Pharm Ind Co Ltd | Derivados de glucagon como agentes hipoglucemicos y antiobesidad |
| FI3322437T3 (fi) * | 2015-06-30 | 2024-02-20 | Hanmi Pharmaceutical Co Ltd | Glukagonijohdannainen ja sen pitkävaikutteisen konjugaatin käsittävä koostumus |
| TWI622596B (zh) | 2015-10-26 | 2018-05-01 | 美國禮來大藥廠 | 升糖素受體促效劑 |
| TWI877582B (zh) | 2015-12-31 | 2025-03-21 | 南韓商韓美藥品股份有限公司 | 三重升糖素／ｇｌｐ－１／ｇｉｐ受體促效劑 |
| SG11201811697SA (en) * | 2016-06-29 | 2019-01-30 | Hanmi Pharmaceutical Co Ltd | Glucagon derivative, conjugate thereof, composition comprising same and therapeutic use thereof |
| CN110545849A (zh) | 2017-02-03 | 2019-12-06 | 韩美药品株式会社 | 具有增加的持续性的生理活性物质的缀合物及其应用 |
| EP3708661A4 (en) * | 2017-12-22 | 2021-12-01 | Hanmi Pharm. Co., Ltd. | THERAPEUTIC ENZYMFUSION PROTEIN WITH A NEW STRUCTURE AND ITS USE |
| KR20200134213A (ko) * | 2018-01-23 | 2020-12-01 | 엑스에리스 파머수티클스, 인크. | 소 용량의 안정한 글루카곤을 사용한 베리아트릭 후 저혈당증의 치료 |
| US20220064248A1 (en) | 2018-12-21 | 2022-03-03 | HANMl PHARM. CO., LTD | Pharmaceutical composition including insulin and glucagon |
| CN109836486B (zh) * | 2019-01-30 | 2020-09-08 | 北京双因生物科技有限公司 | 成纤维生长因子21变体、其融合蛋白及其用途 |
| WO2021235907A1 (ko) | 2020-05-22 | 2021-11-25 | 한미약품 주식회사 | 글루카곤 유도체의 지속형 결합체의 액상 제제 |
| MX2023000698A (es) | 2020-07-15 | 2023-04-18 | Hanmi Pharmaceutical Co Ltd | Uso terapeutico del derivado de glucagon o conjugado del mismo para enfermedades hepaticas. |
| AU2022254588A1 (en) | 2021-04-09 | 2023-09-21 | Hanmi Pharm. Co., Ltd. | Pharmaceutical composition for preventing or treating chronic renal disease including glucagon derivative |
| KR20230095666A (ko) | 2021-12-22 | 2023-06-29 | 한미약품 주식회사 | 간 표적 물질 및 이의 용도 |
| CN115536739B (zh) * | 2022-07-04 | 2023-04-14 | 北京惠之衡生物科技有限公司 | 一种glp-1受体和gcg受体共激动多肽衍生物的制备方法 |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5408037A (en) | 1991-01-17 | 1995-04-18 | Zymogenetics, Inc. | Methods for detecting glucagon antagonists |
| GB9423277D0 (en) | 1994-11-18 | 1995-01-11 | Univ Nottingham | Pulsed laser deposition of coatings |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| CA2249195A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
| US6677136B2 (en) | 2000-05-03 | 2004-01-13 | Amgen Inc. | Glucagon antagonists |
| EP1411968B1 (en) | 2001-07-31 | 2008-09-17 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Glp-1 exendin-4 peptide analogs and uses thereof |
| HRP20050683A2 (en) | 2003-03-19 | 2006-07-31 | Eli Lilly And Company | Polyethylene glycol linked glp-1 compounds |
| CN1723220A (zh) | 2003-11-13 | 2006-01-18 | 韩美药品工业株式会社 | 含有免疫球蛋白fc区作为载体的药物组合物 |
| US8263084B2 (en) | 2003-11-13 | 2012-09-11 | Hanmi Science Co., Ltd | Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate |
| EP2574624A1 (en) | 2006-04-20 | 2013-04-03 | Amgen Inc. | GLP-1 compounds |
| US20090098130A1 (en) | 2007-01-05 | 2009-04-16 | Bradshaw Curt W | Glucagon-like protein-1 receptor (glp-1r) agonist compounds |
| WO2008086086A2 (en) | 2007-01-05 | 2008-07-17 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting enhanced solubility in physiological ph buffers |
| JP2008169195A (ja) | 2007-01-05 | 2008-07-24 | Hanmi Pharmaceutical Co Ltd | キャリア物質を用いたインスリン分泌ペプチド薬物結合体 |
| EP2111414B1 (en) * | 2007-02-15 | 2014-07-02 | Indiana University Research and Technology Corporation | Glucagon/glp-1 receptor co-agonists |
| JP5385266B2 (ja) | 2007-06-15 | 2014-01-08 | ジーランド ファーマ アクティーゼルスカブ | グルカゴン類似体 |
| KR20100049032A (ko) | 2007-06-19 | 2010-05-11 | 오츠카 가가쿠 가부시키가이샤 | 당사슬 부가 ｇｌｐ―１ 펩티드 |
| JP5476304B2 (ja) * | 2007-09-05 | 2014-04-23 | ノボ・ノルデイスク・エー／エス | グルカゴン様ペプチド−１誘導体及びそれらの医薬用途 |
| EP2249853A4 (en) | 2008-01-30 | 2012-12-26 | Univ Indiana Res & Tech Corp | ESTER BASED PEPTIDE PRODRUGS |
| CN104447980A (zh) * | 2008-06-17 | 2015-03-25 | 印第安纳大学研究及科技有限公司 | 在生理pH缓冲液中具有增强的溶解性和稳定性的胰高血糖素类似物 |
| AU2009274425B2 (en) | 2008-06-17 | 2014-05-15 | Indiana University Research And Technology Corporation | GIP-based mixed agonists for treatment of metabolic disorders and obesity |
| WO2010096052A1 (en) | 2009-02-19 | 2010-08-26 | Merck Sharp & Dohme Corp. | Oxyntomodulin analogs |
| CN102459325B (zh) | 2009-06-16 | 2015-03-25 | 印第安纳大学科技研究有限公司 | 胃抑胜肽受体活化的胰高血糖素化合物 |
| WO2011006497A1 (en) | 2009-07-13 | 2011-01-20 | Zealand Pharma A/S | Acylated glucagon analogues |
| GB0917072D0 (en) | 2009-09-29 | 2009-11-11 | Univ Ulster | Peptide analogues of glucagon for diabetes therapy |
| WO2011075393A2 (en) | 2009-12-18 | 2011-06-23 | Indiana University Research And Technology Corporation | Glucagon/glp-1 receptor co-agonists |
| US20130157953A1 (en) | 2010-01-20 | 2013-06-20 | Zealand Pharma A/S | Treatment of cardiac conditions |
| US20130035285A1 (en) * | 2010-03-26 | 2013-02-07 | Novo Nordisk A/S | Novel glucagon analogues |
| JP6050746B2 (ja) | 2010-05-13 | 2016-12-21 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation | Ｇタンパク質共役受容体活性を示すグルカゴンスーパーファミリーのペプチド |
| KR101382593B1 (ko) | 2010-07-21 | 2014-04-10 | 한미사이언스 주식회사 | 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물 |
| CA2821766A1 (en) | 2010-12-22 | 2012-06-28 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting gip receptor activity |
| WO2012150503A2 (en) | 2011-05-03 | 2012-11-08 | Zealand Pharma A/S | Glu-glp-1 dual agonist signaling-selective compounds |
| CN103732617A (zh) | 2011-05-18 | 2014-04-16 | 梅德瑞斯糖尿病有限责任公司 | 用于胰岛素抵抗的改进的肽医药 |
| CA3064214C (en) | 2011-06-10 | 2023-03-07 | Hanmi Science Co., Ltd. | Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same |
| MX353402B (es) * | 2011-06-17 | 2018-01-11 | Hanmi Science Co Ltd | Un conjugado que comprende oxintomodulina y un fragmento de inmunoglobulina, y uso del mismo. |
| US9944687B2 (en) | 2011-07-04 | 2018-04-17 | Imperial Innovations Limited | Compounds and their effects on feeding behaviour |
| EP2780031B1 (en) * | 2011-11-17 | 2018-03-07 | Indiana University Research and Technology Corporation | Glucagon superfamily peptides exhibiting glucocorticoid receptor activity |
| KR20150023013A (ko) | 2012-06-21 | 2015-03-04 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | 수용체 활성을 나타내는 글루카곤 유사체 |
| AU2013277372B2 (en) | 2012-06-21 | 2018-03-29 | Indiana University Research And Technology Corporation | Analogs of glucagon exhibiting GIP receptor activity |
| AR094821A1 (es) | 2012-07-25 | 2015-09-02 | Hanmi Pharm Ind Co Ltd | Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada |
| KR101968344B1 (ko) | 2012-07-25 | 2019-04-12 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물 |
| AR092873A1 (es) | 2012-09-26 | 2015-05-06 | Cadila Healthcare Ltd | Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon |
| KR101993393B1 (ko) | 2012-11-06 | 2019-10-01 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물 |
| SG10201602801YA (en) | 2012-11-06 | 2016-05-30 | Hanmi Pharm Ind Co Ltd | Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment |
| US10005817B2 (en) | 2012-11-20 | 2018-06-26 | Eumederis Pharmaceuticals, Inc. | Peptide pharmaceuticals |
| KR102213907B1 (ko) | 2012-11-20 | 2021-02-09 | 메더리스 다이어비티즈, 엘엘씨 | 인슐린 저항성에 대한 개선된 펩티드 약제 |
| CA2895875A1 (en) | 2012-12-21 | 2014-06-26 | Sanofi | Exendin-4 derivatives |
| WO2014170496A1 (en) | 2013-04-18 | 2014-10-23 | Novo Nordisk A/S | Stable, protracted glp-1/glucagon receptor co-agonists for medical use |
| EP3033355A1 (en) | 2013-08-16 | 2016-06-22 | Medimmune Limited | Gip and glp-1 receptor dual-agonists for the treatment of diabetes |
| WO2015086733A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/glucagon receptor agonists |
| TWI684458B (zh) | 2014-05-30 | 2020-02-11 | 南韓商韓美藥品股份有限公司 | 包含胰島素及ｇｌｐ-１/昇糖素雙重促效劑之治療糖尿病之組成物 |
| TWI802396B (zh) | 2014-09-16 | 2023-05-11 | 南韓商韓美藥品股份有限公司 | 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途 |
| ES2822994T3 (es) | 2014-09-24 | 2021-05-05 | Univ Indiana Res & Tech Corp | Conjugados de incretina-insulina |
| KR102418477B1 (ko) * | 2014-12-30 | 2022-07-08 | 한미약품 주식회사 | 글루카곤 유도체 |
| PE20230304A1 (es) | 2014-12-30 | 2023-02-13 | Hanmi Pharm Ind Co Ltd | Derivados de glucagon como agentes hipoglucemicos y antiobesidad |
| FI3322437T3 (fi) | 2015-06-30 | 2024-02-20 | Hanmi Pharmaceutical Co Ltd | Glukagonijohdannainen ja sen pitkävaikutteisen konjugaatin käsittävä koostumus |
| TW201718629A (zh) * | 2015-09-25 | 2017-06-01 | 韓美藥品股份有限公司 | 包含多個生理多肽及免疫球蛋白Ｆｃ區之蛋白質接合物 |
| TWI877582B (zh) | 2015-12-31 | 2025-03-21 | 南韓商韓美藥品股份有限公司 | 三重升糖素／ｇｌｐ－１／ｇｉｐ受體促效劑 |
-
2015
- 2015-12-30 PE PE2022001996A patent/PE20230304A1/es unknown
- 2015-12-30 UA UAA201707040A patent/UA126960C2/uk unknown
- 2015-12-30 EA EA201791333A patent/EA035527B1/ru not_active IP Right Cessation
- 2015-12-30 AU AU2015372818A patent/AU2015372818A1/en not_active Abandoned
- 2015-12-30 HK HK18104685.2A patent/HK1248713A1/en unknown
- 2015-12-30 TN TN2017000271A patent/TN2017000271A1/en unknown
- 2015-12-30 EP EP15875680.9A patent/EP3241841A4/en not_active Withdrawn
- 2015-12-30 KR KR1020150189532A patent/KR102291020B1/ko active Active
- 2015-12-30 MY MYPI2017000967A patent/MY185334A/en unknown
- 2015-12-30 WO PCT/KR2015/014422 patent/WO2016108586A1/ko not_active Ceased
- 2015-12-30 AR ARP150104340A patent/AR103322A1/es unknown
- 2015-12-30 EP EP19172184.4A patent/EP3575314B1/en active Active
- 2015-12-30 CN CN201580077186.3A patent/CN107636009B/zh active Active
- 2015-12-30 MX MX2017008569A patent/MX2017008569A/es unknown
- 2015-12-30 SG SG11201705376SA patent/SG11201705376SA/en unknown
- 2015-12-30 PH PH1/2017/501222A patent/PH12017501222B1/en unknown
- 2015-12-30 US US15/540,729 patent/US11135271B2/en active Active
- 2015-12-30 CR CR20170293A patent/CR20170293A/es unknown
- 2015-12-30 ES ES19172184T patent/ES2976562T3/es active Active
- 2015-12-30 PE PE2017001168A patent/PE20171154A1/es unknown
- 2015-12-30 JP JP2017535417A patent/JP6797122B2/ja active Active
- 2015-12-30 MA MA40709A patent/MA40709B1/fr unknown
- 2015-12-30 TW TW104144427A patent/TW201639878A/zh unknown
-
2017
- 2017-06-27 IL IL253206A patent/IL253206B/en unknown
- 2017-06-27 CO CONC2017/0006308A patent/CO2017006308A2/es unknown
- 2017-06-28 CL CL2017001718A patent/CL2017001718A1/es unknown
- 2017-06-28 GT GT201700150A patent/GT201700150A/es unknown
- 2017-06-28 EC ECIEPI201740923A patent/ECSP17040923A/es unknown
- 2017-06-29 DO DO2017000156A patent/DOP2017000156A/es unknown
- 2017-07-24 ZA ZA2017/05015A patent/ZA201705015B/en unknown
-
2020
- 2020-08-28 JP JP2020144259A patent/JP7079301B2/ja active Active
-
2021
- 2021-03-09 IL IL281375A patent/IL281375B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2017000156A (es) | Derivados de glucagón con estabilidad mejorada | |
| CL2018000684A1 (es) | Moduladores de la proteína de núcleo de la hepatitis b. | |
| ECSP19021223A (es) | Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo | |
| MX2018003388A (es) | Agonistas del receptor farnesoide x y usos de los mismos. | |
| CL2018000299A1 (es) | Composiciones con potenciadores de impregnacion para el suministro de fármacos. | |
| CR20120345A (es) | Derivados de 3-hidroxi-5-arilisotiazol novedosos | |
| UA118558C2 (uk) | Пептидна сполука | |
| CL2016000952A1 (es) | Derivados de carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b | |
| MY187047A (en) | Selective pyy compounds and uses thereof | |
| CL2015002736A1 (es) | Composición farmacéutica de clorhidrato de s-ketamina. | |
| CL2016001918A1 (es) | Heteroaril amidas como inhibidores de agregación de proteína | |
| MX389178B (es) | Formulacion de proporcion fija de insulina glargina/lixisenatida. | |
| CL2017002293A1 (es) | Tratamiento de pacientes con diabetes mellitus de tipo 2 | |
| BR112018015367A2 (pt) | carreadores oromucosais de nanofibra para tratamento terapêutico | |
| MX381944B (es) | Lixisenatida para usarse en el tratamiento de diabetes mellitus de tipo 2 en pacientes pediàtricos. | |
| AR103323A1 (es) | Derivados de glucagón | |
| CL2015001943A1 (es) | Derivados de bencilamina | |
| CL2017001680A1 (es) | Composición farmacéutica para el tratamiento de enfermedades gastrointestinales | |
| EA201891848A1 (ru) | Фармацевтическая композиция для применения в лечении фиброза | |
| CL2022002644A1 (es) | Derivados de glucagón con estabilidad mejorada | |
| CL2022002645A1 (es) | Derivados de glucagón con estabilidad mejorada | |
| CL2022002646A1 (es) | Derivados de glucagón con estabilidad mejorada | |
| AR107282A1 (es) | Agonista triple que tiene actividad para un receptor de glucagón, un receptor del péptido 1 similar al glucagón (glp-1) y un receptor de péptido insulinotrópico dependiente de glucosa (gip) | |
| MX2016016635A (es) | Desmopresina estabilizada. | |
| MX390488B (es) | Composicion farmaceutica de clorhidrato de amantadina-loratadina-paracetamol para integrar una capsula, para el tratamiento de refriados entre otras alopatias. |